Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011703 | 0.90 | CA1 (0.36) | CA2CA1POLBCA7CA14 | |
| SCHEMBL14894716 | 0.82 | CA2 (0.53) | CA2CA1MAPK1 | |
| SCHEMBL2010170 | 0.80 | ALDH1A1 (0.35) | CA2CA1CA7CA14MEN1 | |
| SCHEMBL15484625 | 0.78 | CA2 (0.52) | CA2CA1MAPK1 | |
| SCHEMBL15484663 | 0.76 | CA2 (0.50) | CA2CA1MAPK1MAPT | |
| SCHEMBL15484701 | 0.76 | CA2 (0.50) | CA2CA1MAPK1MAPT | |
| SCHEMBL28308485 | 0.76 | ALDH1A1 (0.47) | CA2CA1CA7CA14MAPK1 | |
| SCHEMBL17363949 | 0.74 | CA2 (0.52) | CA2CA1MAPK1SMN1; SMN2 | |
| SCHEMBL5326388 | 0.74 | CA2 (0.70) | CA2CA1CA7CA14MAPK1 | |
| SCHEMBL2106254 | 0.74 | CA2 (0.70) | CA2CA1CA7CA14MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365489-B2 | Nitrooxy alkanoic acids and derivatives thereof in feed for reducing methane emission in ruminants, and/or to improve ruminant performance | DSM IP ASSETS B.V. (NL) | 2016-06-14 | — | — | US | disclosed |
| US-8784871-B2 | Nitrooxy alkanoic acids and derivatives thereof in feed for reducing methane emission in ruminants, and/or to improve ruminant performance | DSM IP ASSETS B.V. (NL) | 2014-07-22 | — | — | US | disclosed |
| US-20140134282-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2014-05-15 | — | — | US | disclosed |
| EP-2509435-B1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS BV (NL) | 2014-02-26 | — | — | EP | disclosed |
| US-20120315339-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2012-12-13 | — | — | US | disclosed |
| EP-2509435-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP Assets B.V. (NL) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070133-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2011-06-16 | — | — | WO | disclosed |
| US-20110086847-A1 | THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086847-A1 | THIADIAZOLE MODULATORS OF BETA ADRENERGIC RECEPTOR | ADRB3, ADRB2, ADRB1 | CA2 3774/4885CA1 4869/4885POLB 4158/4885 |
| US-20140134282-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | PIGS, TECR, CYP4X1 | CA2 1208/4885CA1 1747/4885POLB 2582/4885 |
| US-20120315339-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | PIGS, TECR, CYP4X1 | CA2 1208/4885CA1 1747/4885POLB 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.